Kairos Pharma’s goal is to intervene early in resistance and re-sensitize cancer cells to therapy: CEO October 14, 2025
JNJ Earnings: Key quarterly highlights from Johnson & Johnson’s Q3 2025 financial results October 14, 2025
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials June 9, 2025
